Abstract:Abstract In recent years there has been much discussion and exploration for a chemopreventive agent for skin cancer. This is something of particular interest for our transplant patients, who are at high risk of developing skin cancers, particularly keratinocyte cancers (KCs). Previous studies have highlighted benefit in immune-competent patients. A recent study by Allen et al. (Allen NC, Martin AJ, Snaider VA et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N Engl J Med 2023; 388: 804–12) sought to investigate whether oral nicotinamide supplementation in organ transplant recipients provided any benefit. Their study demonstrated a 24% reduction in invasive SCCs in the nicotinamide group, but overall did not demonstrate a statistically significant reduction in KCs or precursor lesions. Some have challenged that the outcome of this trial will define future chemoprevention practices. We aimed to better define nicotinamide prescribing by surveying all members of the Irish Association of Dermatologists with a 13-item questionnaire focusing on barriers to and thresholds for prescribing oral nicotinamide chemoprevention. We asked respondents how often they prescribe oral nicotinamide for chemoprevention for the following indications: (i) ‘A patient with sun-damaged skin but no focal actinic keratosis’, (ii) ‘Patient with focal actinic keratosis but no history of KC’, (iii) ‘Patient with field actinic change but no history of KC’, (iv) ‘At the time of diagnosis of first KC’ and (v) ‘Patient with more than one KC’. We applied these scenarios for both immunocompetent and immunosuppressed patients. In total, 81% of respondents reported that they prescribe oral nicotinamide for KC chemoprevention. For all chemoprevention indications, we found increased nicotinamide prescribing for immunosuppressed patients. The majority of nicotinamide prescribers introduce treatment in immunocompetent patients at the time of first KC diagnosis (48%) and prescribed oral nicotinamide ‘often’ if the patient had more than one KC (55%). For the same indications in the immunosuppressed cohort, rates of prescribing were 62.5% and 69%, respectively. For secondary chemoprevention, prescribing of nicotinamide (67%) is favoured over acitretin (20%) or a combination of both (11%) in patients at highest KC risk. Overall, 20% of respondents do not prescribe nicotinamide, citing the following reasons as barriers: lack of evidence (50%), cost to patient (22%) and lack of availability (14%). Closer surveillance and changing immunosuppressive protocols reducing skin cancer risk make it difficult to distil the chemopreventive effects of nicotinamide. Our study highlights high current rates of oral nicotinamide prescribing among Irish dermatologists, as secondary chemoprevention particularly in immunosuppressed patients. This baseline will allow for monitoring of potential future changes to skin cancer chemopreventive prescribing patterns among dermatologists. The use of nicotinamide, a drug with a well-established safety profile and favourable price point, warrants further studies before its chemopreventive potential is discounted.

BI22 A UK multicentre prospective study on the awareness and impact of azathioprine as a major risk factor for developing skin cancer in patients with inflammatory bowel disease: patient and clinician perspectives

Azathioprine, risk of skin cancer and use of photoprotection: a cross-sectional survey of patients with inflammatory bowel disease and gastroenterology clinicians

BI13 (P065) Attitudes and practices of patients with inflammatory bowel disease towards skin cancer risk and sun protection

P065 Attitudes and practices of patients with inflammatory bowel disease towards skin cancer risk and sun protection

BI23 ‘Not so, my Lord; I am too much i’ the sun.’ Sun protection behaviours and awareness among an immunosuppressed neurology cohort

Analysis of Adverse Drug Reactions of Azathioprine in the Treatment of Patients with Inflammatory Bowel Disease

BI09 Skin cancer burden and dermatological follow-up in solid-organ transplant recipients: a regional study

Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center

P339 Dermatological evaluation of candidates with IBD for biological therapy - should it become part of the scheme during qualification?

P456 Risk of Malignant Tumors in Patients with Autoimmune Diseases on Ustekinumab Therapy: a Systematic Review and Meta-Analysis

P072 Risk of incident cancer, excluding keratinocyte carcinoma, in patients with psoriasis treated with biologic therapy: a prospective cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group

P064 Prevention is better than cure: acitretin and chemoprevention

Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients

O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group

BI08 Delivery of stratified skin cancer surveillance in solid-organ transplant recipients: development of a consensus statement on behalf of the British Society for Skin Care in Immunosuppressed Individuals

Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study

Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies

Update on skin cancer prevention modalities and screening protocols in solid organ transplant recipients: a scoping review

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

BI14 Nicotinamide prescribing for skin cancer chemoprevention: the Irish experience

P704 Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE Registry